Shivaani Kummar

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Targeting of Wnt–β-Catenin Pathway in Recurrent Ameloblastoma

  New England Journal of Medicine · 2026-06-03

• Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I

  JCO Precision Oncology · 2026-06-01

• Lipid Nanoparticle–Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors

  Clinical Cancer Research · 2026-05-18

• Multiplex immunofluorescence microscopy assays for pharmacodynamic assessment of MET tyrosine kinase activation in the plasma membrane and nucleus

  PLoS ONE · 2026-05-12

• Abstract PS3-06-22: Artificial Intelligence Predicts OncotypeDX Recurrence Scores Directly from H&E-Stained Whole Slide Images of ER+/HER2- Node-Negative Breast Cancer Surgical Sections

  Clinical Cancer Research · 2026-02-17

• Abstract PS5-03-17: Ai-derived Morphometric And Transcriptomic Biomarkers From H&E-stained Images Predict Response To Durvalumab And Olaparib In Metastatic Triple Negative Breast Cancer

  Clinical Cancer Research · 2026-02-17

• Abstract PD11-05: Inferring Spatial Genomic Expression profiles from H&E-Stained Histology Using Weakly Supervised Deep Learning in Breast Cancer

  Clinical Cancer Research · 2026-02-17

• Abstract PS3-06-24: Transcriptomics-guided AI outperforms and expands on OncotypeDX to predict Hormonal therapy response and Chemotherapy benefit from H&E-stained Whole Slide images in ER+/HER2- Breast Cancer

  Clinical Cancer Research · 2026-02-17

• A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

  Cancer Chemotherapy and Pharmacology · 2025-12-22

• LBA2 Rezatapopt for advanced solid tumours with a TP53 Y220C mutation: Initial analysis of the PYNNACLE phase II study

  Annals of Oncology · 2025-12-01

• CTNI-10. A PHASE 1/2 TRIAL OF FOG-001, A FIRST-IN-CLASS DIRECT β-CATENIN:TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN ADAMANTINOMATOUS CRANIOPHARYNGIOMA (ACP) PATIENTS

  Neuro-Oncology · 2025-11-01

• 580 Phase 1 study of mitotic checkpoint inhibitor BAL0891 in combination with tislelizumab (anti-PD-1 antibody) in patients with advanced solid tumors

  Regular and Young Investigator Award Abstracts · 2025-11-01 · 1 citations

• Abstract B031: A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+)

  Molecular Cancer Therapeutics · 2025-10-22 · 2 citations

• Abstract B003: Orally administered MOMA-341 as monotherapy or combination therapy in participants with advanced or metastatic solid tumors: Phase 1 study design

  Molecular Cancer Therapeutics · 2025-10-22 · 2 citations

• The generalized 3+3 (G3) design for Phase I trials: A design for clinicians

  Contemporary Clinical Trials · 2025-09-13

• PYNNACLE phase II trial assessing rezatapopt (PC14586), a selective p53 reactivator, in patients with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation

  Gynecologic Oncology · 2025-09-01

• 2688MO A phase I/II trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor - Safety and preliminary antitumor activity in patients with desmoid tumors

  Annals of Oncology · 2025-09-01 · 2 citations

• The roles of mutant p53 in reprogramming and inflammation in breast cancers

  Cell Death and Differentiation · 2025-07-22 · 5 citations

• Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors

  JCO Precision Oncology · 2025-07-01 · 2 citations

• Abstract P3-12-27: Phase 1 Analysis from the PYNNACLE Phase 1/2 Study of Rezatapopt in the Subgroup of Patients with Advanced Breast Cancer Harboring a TP53 Y220C Mutation

  Clinical Cancer Research · 2025-06-13 · 1 citations